Investment
Growth asset coverage for advisers, including domestic and global equities, emerging markets, and high-conviction strategies.
- Contributor
- Dion Hershan
- Drew Meredith
- Emanuel Datt
- Francyne Mu
- Giselle Roux
- Greg Bright
- Ishan Dan
- James Dunn
- Lachlan Maddock
- Laurence Parker-Brown
- Michael Block
- Mishan Dahia
- Nick Hatzis
- Nicki Bourlioufas
- Peter McPhee
- Rob Perrone, Eric Marais & Shane Woldendorp
- Staff Writer
- Tahn Sharpe
- The Inside Adviser
- Tom King
- Tyndall Asset Management Australian Small Companies Team
- Will Arnost
- Yarra Capital Management
Thinking forward: Three ASX biotech stars
And still they keep coming – here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. As always,...
Growth managers continue to shine
It’s been a while since “value investing” made sense: the style has suffered a dreadful stretch of performance since the 2008 financial...
Sizing up the smalls
Generalising is a dark art. The moment one observes an apparent pattern, idiosyncratic data jumps out. Judging small-cap managers falls into this trap....
Introducing the NEATs
Video games have traditionally been associated with laziness, requiring someone to stay at home in a dark room when they could be doing more...
What's better than a unicorn?
The stellar run in the Nasdaq 100 index, which has seen it reach new all-time highs some 40 times already in 2020, shows no signs of slowing. With such...
HESTA appoints Martin Currie for new partnership
Martin Currie Investment Management has formed a partnership for international equities with HESTA, the $52 billion health and related industries super fund.
The power of engagement
Investing to improve lives is the mantra of Martin Currie, one of the world leaders in ESG investing. This annual report reviews the year that was...
3 unlikely stocks to get your dividend fix
One of the main themes that played out this reporting season was the absence of company dividends. The cash doled out by the largest 50 ASX listed companies...
Look to Your Own Devices: Biotech Stars of the ASX
In the first of a series on Australian biotech success stories, we start with some of the outstanding medical device stocks on the ASX.
E is not for easy
Recent years have had pundits focus on the potential growth and relative valuation of emerging markets. The terminology alone is obtuse, just what is emerging?...
Small caps to remain attractive for investors
Following the March equity market correction due to the COVID-19 pandemic, global equity markets rebounded sharply in April, with the small cap sector...